NEW BRUNSWICK, N.J. / Dec 10, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22 nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months Results add to the overall survival (OS) benefits recently presented, as the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3... Read More

Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches used to manage the condition There are no FDA-approved therapies indicated for wAIHA, and patients living with this condition need targeted treatment options with a proven safety and efficacy profile Johnson & Johnson is... Read More

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10 -6 ) with DARZALEX FASPRO ® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations disproportionately impacted by multiple myeloma SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data... Read More

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and... Read More

First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) significantly delayed progression... Read More

Applications filed for TREMFYA ® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis SPRING HOUSE, Pa. , Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ® (guselkumab) for the treatment of children 6 years and older... Read More

Following recent U.S. FDA approval of TREMFYA ® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remission at Week 12 and met all secondary endpoints in adults with... Read More

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI ® reduced the risk of disease progression or death by 74 per cent compared to standard of care. 1 TORONTO , Nov. 21, 2024 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI ® (ciltacabtagene autoleucel) for the treatment of adult... Read More

More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic malignancies RARITAN, N.J. , Nov. 19, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented... Read More

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 Comprehensive results are being prepared for presentation at upcoming medical congresses SPRING HOUSE, Pa. , Nov. 18, 2024 /PRNewswire/ -- Johnson &... Read More

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS... Read More

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on average who received nipocalimab 15 mg/kg compared to participants who... Read More

If approved, DARZALEX FASPRO ® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage RARITAN, N.J. , Nov. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug... Read More

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA ® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in ClinESSDAI score from baseline and other key efficacy endpoints at Week 24... Read More

BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- I novalon , a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary executives to the stage at Empower 2024 , sparking meaningful conversations with leaders from every corner of healthcare. The annual summit, focused on the intersection of healthcare and technology, welcomed attendees in Washington,... Read More

A greater number of patients treated with subcutaneous TREMFYA ® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pending FDA approval PHILADELPHIA , Oct. 28, 2024 /PRNewswire/ -- Johnson... Read More

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living with moderate to severe plaque psoriasis LAS VEGAS , Oct. 25, 2024 /PRNewswire/... Read More

New five-year data reinforce long-term safety and efficacy of SPRAVATO ® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression) 23 abstracts highlight data from Company's robust portfolio and pipeline, including clinical insights on major depressive disorder and the significant burden of anhedonia and insomnia symptoms Large real-world analysis highlights the... Read More

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChR a positive adolescents (aged 12 – 17 years) living with... Read More

NEW BRUNSWICK, N.J. / Oct 15, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At... Read More

2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%* 2024 Third-Quarter Earnings per share (EPS) of $1.11 decreasing by 34.3% due to a one-time special charge and acquired IPR&D. Adjusted EPS of $2.42 decreasing by 9.0%* with acquired IPR&D impacting results approximately 1,900 basis points Significant pipeline progress including approvals... Read More

NEW BRUNSWICK, N.J. / Oct 10, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18 th , at the Lotte New York Palace in New York. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration , will represent the Company in a session scheduled at 10:55 a.m. (Eastern Time). This live audio webcast will be available to investors and... Read More

TREMFYA ® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA ® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved... Read More

Adds V-Wave’s Novel and Minimally Invasive Ventura ® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease NEW BRUNSWICK, N.J. / Oct 09, 2024 / Business Wire / Johnson & Johnson 1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options... Read More

NEW BRUNSWICK, N.J. / Oct 04, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12 th , at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology , will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time).... Read More

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal , Oct. 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA ® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to... Read More

Results from CEPHEUS study highlight DARZALEX FASPRO ® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint RARITAN, N.J. , Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today... Read More

The new full visual range IOL* 1 delivers exceptional distance vision 2 and 14% smaller readable print size vs PanOptix 3 † . 93% of patients become free from glasses at all distances. #4 ‡ TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes. 5¶ JACKSONVILLE, Fla. , Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson § , a global leader... Read More

45 percent reduction in risk of death achieved with CARVYKTI ® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI ®... Read More

Minimal residual disease (MRD)-negativity rate of 10 -5 more than doubled by 12 months with DARZALEX FASPRO ® in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from three studies highlighting clinical efficacy of DARZALEX ® (daratumumab) and DARZALEX FASPRO ®... Read More

Study of the first and only subcutaneous quadruplet regimen demonstrates 60.9 percent improvement in minimal residual disease (MRD)-negativity and 43 percent reduction in the risk of progression or death Phase 3 CEPHEUS study results presented in late-breaking oral presentation at the International Myeloma Society (IMS) Annual Meeting RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced... Read More

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY ® and TECVAYLI ® monotherapies RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibody combination of TALVEY ® (talquetamab-tgvs), the first and only FDA-approved... Read More

Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody Safety profile, including infection rates, similar to TALVEY ® and DARZALEX FASPRO ® monotherapies RIO DE JANEIRO , Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced updated results from the... Read More

Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately $8 Billion NEW BRUNSWICK, N.J. / Sep 20, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case... Read More

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, N.J. , Sept. 17, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT ® (amivantamab-vmjw) in combination with standard of care chemotherapy (carboplatin and... Read More

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, Spain , Sept. 16, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab (CET) achieved nearly double the... Read More

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, Spain , Sept. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the... Read More

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b /2 OrigAMI-1 study, which showed RYBREVANT ® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated... Read More

Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT ® (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with... Read More

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program 1,2,3,4,5 TREMFYA ® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis HORSHAM, Pa. , Sept. 11, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today... Read More

Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ® , a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of... Read More

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT ® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker oral presentation at WCLC SAN DIEGO , Sept. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced longer follow-up data from the landmark Phase 3 MARIPOSA study which... Read More

NEW BRUNSWICK, N.J. / Sep 05, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15 th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ SPRING HOUSE, Pa. , Aug. 29, 2024... Read More

Four RYBREVANT ® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, N.J. , Aug. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company's industry-leading solid tumor portfolio and pipeline will be featured at the 2024... Read More

NEW BRUNSWICK, N.J. / Aug 26, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Dr. Peter M. Fasolo will retire from his position as Executive Vice President, Chief Human Resources Officer at the end of this year, following 16 years of leadership and service to the Company. Throughout his distinguished career, Dr. Fasolo has worked with the organization’s Board of Directors and partnered with three... Read More

V-Wave’s Novel and Minimally Invasive Interatrial Shunt is Designed to Treat Heart Failure and Addresses Significant Treatment Gap Device Further Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular NEW BRUNSWICK, N.J. / Aug 20, 2024 / Business Wire / Johnson & Johnson 1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on... Read More

RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response RARITAN, N.J. , Aug. 20, 2024 /PRNewswire/ --... Read More

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT) The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN)... Read More

Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO ® showed 60 percent reduction in risk of disease progression or death New regimen solidifies DARZALEX FASPRO ® as a foundational frontline therapy in multiple myeloma with potential to significantly delay disease progression HORSHAM, Pa. , July 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug... Read More

NEW BRUNSWICK, N.J. / Jul 29, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5 th , at the Encore Boston Harbor, Evertte, MA. Tim Schmid, Executive Vice President, WorldWide Chairman, MedTech will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to investors and other... Read More

NEW BRUNSWICK, N.J. / Jul 23, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4 th , held at the New York Marriott Marquis, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer and John Reed, Executive Vice President, Innovative Medicine, R&D will represent the Company in a session scheduled at 10:45 am... Read More

Phase 4 SPRAVATO ® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO ® TITUSVILLE, N.J. , July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a... Read More

NEW BRUNSWICK, N.J. / Jul 17, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is August 27, 2024. About Johnson & Johnson At Johnson... Read More

2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* Significant new product pipeline progress including TREMFYA IBD and... Read More

NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases NEW BRUNSWICK, N.J. / Jul 11, 2024 / Business Wire / Johnson & Johnson 1 (NYSE: JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a... Read More

Phase 3 PAPILLON study showed RYBREVANT ® in combination with carboplatin and pemetrexed significantly improved progression-free survival, reducing the risk of disease progression or death by 60 per cent versus carboplatin and pemetrexed alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations. 1 TORONTO , July 3, 2024 /CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada,... Read More

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J. , July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI ® (ciltacabtagene autoleucel;... Read More

First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADL a ) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+ HELSINKI , June 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG).... Read More

Acquisition includes two pre-clinical bispecific antibodies targeting proven disease pathways, offering the potential to transform the treatment paradigm for patients living with atopic dermatitis and other immune-mediated diseases NEW BRUNSWICK, N.J. / Jun 21, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held... Read More

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA ® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's disease GALAXI includes data demonstrating superior outcomes for... Read More

TREMFYA ® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. , June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA ® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease. 1 The study met both co-primary... Read More

Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free survival and duration of response also observed with subcutaneous amivantamab RARATIN, N.J. , June 17, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application... Read More

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments VIENNA , June 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated... Read More

24-month overall survival rate of 67 percent achieved with TALVEY ® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID , June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated... Read More

Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease NEW BRUNSWICK, N.J. / May 31, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit... Read More

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN,... Read More

The Company 1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary 2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patients Johnson & Johnson is committed to... Read More

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential to provide best-in-disease therapeutics for people with moderate to severe AD and asthma These pipeline additions demonstrate the Company’s strategic approach to build a portfolio of... Read More

NEW BRUNSWICK, N.J. / May 08, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference on Wednesday, June 12 th , at the Loews Miami Beach Hotel, Miami Beach, Florida. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and John Reed, Executive Vice President, Innovative Medicine R&D will represent the Company in a... Read More

The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States NEW BRUNSWICK, N.J. / May 01, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced a proposed Plan of Reorganization (the “Plan”) by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian... Read More

NEW BRUNSWICK, N.J. / Apr 22, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein’s 40 th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29 th , at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time). This live audio webcast will be available to investors and... Read More

NEW BRUNSWICK, N.J. / Apr 16, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62 nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend... Read More

2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* Company increasing the midpoint for Full-Year 2024 operational sales 5 and adjusted operational EPS guidance NEW... Read More

NEW BRUNSWICK, N.J. / Apr 08, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15 th , at the InterContinental Barclay Hotel, New York. Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to... Read More

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI ® in 1-3 prior lines of therapy reduced the risk of disease progression or death by 59 percent compared to standard therapies HORSHAM, Pa. , April 5, 2024... Read More

Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss... Read More

NEW BRUNSWICK, N.J. / Apr 04, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash. TRC Capital Investment’s offer price of $151.23 per share is approximately 4.12% lower than the... Read More

NEW BRUNSWICK, N.J. / Apr 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14 th , at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time). This live audio webcast will be available to investors and other interested... Read More

NEW BRUNSWICK, N.J. / Mar 11, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16 th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics NEW BRUNSWICK, N.J. / Mar 07, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary... Read More

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT ® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National Comprehensive Cancer Network ® (NCCN ® ) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) to recommend... Read More

Biweekly dosing with TECVAYLI ® , the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa. , Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13 th , at the Loews Miami Beach Hotel, Miami Beach, FL. Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time). This live audio webcast will be available to... Read More

NEW BRUNSWICK, N.J. / Feb 12, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12 th , at the Fontainebleau Miami Beach, FL. Joe Wolk, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested... Read More

NEW BRUNSWICK, N.J. / Feb 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45 th Annual Institutional Investors Conference on Tuesday, March 5 th , at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). This live audio webcast will be available to... Read More

2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of 10.9%* 2023 Fourth-Quarter Earnings per share (EPS) of $1.70 increasing 39.3% and adjusted EPS of $2.29 increasing by 11.7%* 2023 Full-Year reported sales growth of 6.5% to $85.2 Billion with operational growth of 7.4%* and adjusted... Read More

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics NEW BRUNSWICK, N.J. / Jan 08, 2024 / Business Wire / Johnson & Johnson... Read More

NEW BRUNSWICK, N.J. / Jan 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2024 of $1.19 per share on the company’s common stock. The dividend is payable on March 5, 2024 to shareholders of record at the close of business on February 20, 2024. The ex-dividend date is February 16, 2024. About Johnson & Johnson At Johnson... Read More

NEW BRUNSWICK, N.J. / Dec 11, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23 rd to review fourth-quarter results. Joaquin Duato, Chairman and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other interested parties... Read More

NEW BRUNSWICK, N.J. / Dec 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 th , at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time) This live audio webcast will be available to investors and other... Read More

Provides long-term operational sales outlook, including: Enterprise Compound Annual Growth Rate (CAGR) of 5-7% 1* for 2025-2030 Innovative Medicine CAGR of 5-7% 1* for 2025-2030; expects 10+ assets with peak year sales (PYS) 2 potential of $5B+* and another 15+ assets with PYS 2 potential of $1-5B* MedTech in the upper range of its markets, which are growing 5-7% 3 for 2022-2027, with one third of 2027 sales coming from new... Read More

NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors. “Mr. Woods is an exceptional addition to Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Mr. Woods has an impressive career of leading... Read More

Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson MedTech 1 today announced the completion of the acquisition 2 of Laminar, Inc., a privately-held medical device company focused on... Read More

NEW BRUNSWICK, N.J. / Nov 16, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the ‘Company’) will hold an Enterprise Business Review for the investment community on Tuesday, December 5, 2023. During the event, Company leaders will share a detailed review of the Innovative Medicine and MedTech businesses and their respective pipelines as well as discuss the Company’s long-term strategy to deliver sustained growth and... Read More

NEW BRUNSWICK, N.J. / Oct 23, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is stepping down from her position to pursue other opportunities. Ms. McEvoy will remain with the Company into Q1 2024 to support a successful transition. Tim Schmid has been appointed... Read More

NEW BRUNSWICK, N.J. / Oct 19, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2023 of $1.19 per share on the company’s common stock. The dividend is payable on December 5, 2023 to shareholders of record at the close of business on November 21, 2023. The ex-dividend date is November 20, 2023. About Johnson & Johnson At... Read More

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%* Earnings per share (EPS) of $1.69 increasing 4.3% and adjusted EPS of $2.66 increasing by 19.3%* Company is increasing 2023 full-year guidance midpoints for sales 5 and adjusted EPS NEW BRUNSWICK, N.J. / Oct 17, 2023 / Business Wire... Read More

NEW BRUNSWICK, N.J. / Sep 18, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 17 th to review third-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional... Read More